Behandlingseffekten på reumatoid artritis for de tre eksisterende tumornekrosefaktor-alpha-haemmende behandlinger. Metaanalytisk litteraturstudie--sekundaerpublikation

Robin Christensen; Lars Erik Kristensen; Pierre Geborek; Bente Danneskiold-Samsøe; Tore Saxne; Henning Bliddal; Robin Christensen; Lars Erik Kristensen; Pierre Geborek; Bente Danneskiold-Samsøe; Tore Saxne; Henning Bliddal

Behandlingseffekten på reumatoid artritis for de tre eksisterende tumornekrosefaktor-alpha-haemmende behandlinger. Metaanalytisk litteraturstudie--sekundaerpublikation

Robin Christensen, Lars Erik Kristensen, Pierre Geborek, Bente Danneskiold-Samsøe, Tore Saxne, Henning Bliddal, Robin Christensen, Lars Erik Kristensen, Pierre Geborek, Bente Danneskiold-Samsøe, Tore Saxne, Henning Bliddal

3 Citationer (Scopus)

Abstract

Absolute treatment efficacy (via number needed to treat) of rheumatoid arthritis for each of the three available anti tumour necrosis factor alpha inhibiting therapies. Our aim was to indirectly compare the long-term efficacy of the available anti-tumour necrosis factor (TNF) therapies in patients with established rheumatoid arthritis. The results indicate that the absolute efficacy associated with use of these anti-TNF therapies is equivalent if applied in equivalent dosages. In standard dosages, infliximab (3 mg/kg/eight weeks) is only half as effective as adalimumab (40 mg/two weeks) and etanercept (25 mg twice weekly).
Udgivelsesdato: 2009-Jun

Bidragets oversatte titel	The efficacy of the three available anti-tumour necrosis factor therapies in patients with rheumatoid arthritis. A meta-analytic literature review--secondary publication
Originalsprog	Dansk
Tidsskrift	Ugeskrift for læger
Vol/bind	171
Udgave nummer	26
Sider (fra-til)	2192-4
Antal sider	3
ISSN	0041-5782
Status	Udgivet - 2009

Citationsformater

Christensen, R., Kristensen, L. E., Geborek, P., Danneskiold-Samsøe, B., Saxne, T., Bliddal, H., Christensen, R., Kristensen, L. E., Geborek, P., Danneskiold-Samsøe, B., Saxne, T., & Bliddal, H. (2009). Behandlingseffekten på reumatoid artritis for de tre eksisterende tumornekrosefaktor-alpha-haemmende behandlinger. Metaanalytisk litteraturstudie--sekundaerpublikation. Ugeskrift for læger, 171(26), 2192-4.

Behandlingseffekten på reumatoid artritis for de tre eksisterende tumornekrosefaktor-alpha-haemmende behandlinger. Metaanalytisk litteraturstudie--sekundaerpublikation. / Christensen, Robin; Kristensen, Lars Erik; Geborek, Pierre et al.

I: Ugeskrift for læger, Bind 171, Nr. 26, 2009, s. 2192-4.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Christensen, R, Kristensen, LE, Geborek, P, Danneskiold-Samsøe, B, Saxne, T, Bliddal, H, Christensen, R, Kristensen, LE, Geborek, P, Danneskiold-Samsøe, B, Saxne, T & Bliddal, H 2009, 'Behandlingseffekten på reumatoid artritis for de tre eksisterende tumornekrosefaktor-alpha-haemmende behandlinger. Metaanalytisk litteraturstudie--sekundaerpublikation', Ugeskrift for læger, bind 171, nr. 26, s. 2192-4.

@article{cd5b9f8077a411df928f000ea68e967b,

title = "Behandlingseffekten p{\aa} reumatoid artritis for de tre eksisterende tumornekrosefaktor-alpha-haemmende behandlinger. Metaanalytisk litteraturstudie--sekundaerpublikation",

abstract = "Absolute treatment efficacy (via number needed to treat) of rheumatoid arthritis for each of the three available anti tumour necrosis factor alpha inhibiting therapies. Our aim was to indirectly compare the long-term efficacy of the available anti-tumour necrosis factor (TNF) therapies in patients with established rheumatoid arthritis. The results indicate that the absolute efficacy associated with use of these anti-TNF therapies is equivalent if applied in equivalent dosages. In standard dosages, infliximab (3 mg/kg/eight weeks) is only half as effective as adalimumab (40 mg/two weeks) and etanercept (25 mg twice weekly). Udgivelsesdato: 2009-Jun",

author = "Robin Christensen and Kristensen, {Lars Erik} and Pierre Geborek and Bente Danneskiold-Sams{\o}e and Tore Saxne and Henning Bliddal and Robin Christensen and Kristensen, {Lars Erik} and Pierre Geborek and Bente Danneskiold-Sams{\o}e and Tore Saxne and Henning Bliddal",

note = "Keywords: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Immunoglobulin G; Receptors, Tumor Necrosis Factor; Treatment Outcome",

year = "2009",

language = "Dansk",

volume = "171",

pages = "2192--4",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "26",

}

TY - JOUR

T1 - Behandlingseffekten på reumatoid artritis for de tre eksisterende tumornekrosefaktor-alpha-haemmende behandlinger. Metaanalytisk litteraturstudie--sekundaerpublikation

AU - Christensen, Robin

AU - Kristensen, Lars Erik

AU - Geborek, Pierre

AU - Danneskiold-Samsøe, Bente

AU - Saxne, Tore

AU - Bliddal, Henning

AU - Christensen, Robin

AU - Kristensen, Lars Erik

AU - Geborek, Pierre

AU - Danneskiold-Samsøe, Bente

AU - Saxne, Tore

AU - Bliddal, Henning

N1 - Keywords: Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Immunoglobulin G; Receptors, Tumor Necrosis Factor; Treatment Outcome

PY - 2009

Y1 - 2009

N2 - Absolute treatment efficacy (via number needed to treat) of rheumatoid arthritis for each of the three available anti tumour necrosis factor alpha inhibiting therapies. Our aim was to indirectly compare the long-term efficacy of the available anti-tumour necrosis factor (TNF) therapies in patients with established rheumatoid arthritis. The results indicate that the absolute efficacy associated with use of these anti-TNF therapies is equivalent if applied in equivalent dosages. In standard dosages, infliximab (3 mg/kg/eight weeks) is only half as effective as adalimumab (40 mg/two weeks) and etanercept (25 mg twice weekly). Udgivelsesdato: 2009-Jun

AB - Absolute treatment efficacy (via number needed to treat) of rheumatoid arthritis for each of the three available anti tumour necrosis factor alpha inhibiting therapies. Our aim was to indirectly compare the long-term efficacy of the available anti-tumour necrosis factor (TNF) therapies in patients with established rheumatoid arthritis. The results indicate that the absolute efficacy associated with use of these anti-TNF therapies is equivalent if applied in equivalent dosages. In standard dosages, infliximab (3 mg/kg/eight weeks) is only half as effective as adalimumab (40 mg/two weeks) and etanercept (25 mg twice weekly). Udgivelsesdato: 2009-Jun

M3 - Tidsskriftartikel

SN - 0041-5782

VL - 171

SP - 2192

EP - 2194

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 26

ER -

Behandlingseffekten på reumatoid artritis for de tre eksisterende tumornekrosefaktor-alpha-haemmende behandlinger. Metaanalytisk litteraturstudie--sekundaerpublikation

Abstract

Fingeraftryk

Citationsformater